Phaseline

Targets › FGFR3

FGFR3 (Fibroblast growth factor receptor 3): drug programs, companies and trials

35 programs from 30 companies in 105 trials: 58 Phase 2, 32 Phase 1, 15 Phase 3; Oncology, Gastroenterology, Other; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. (UniProt, P22607)

Open in Phaseline: the race on FGFR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TransThera Sciences (Nanjing)TT-00420 (tinengotinib)
Fibroblast growth factor receptor (FGFR) inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 3Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC)Dec 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
Xynomic PharmaceuticalsPazopanib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory …Dec 2026
Johnson & Johnson (Janssen)Erdafitinib (TAR-210)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 3Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm …Dec 2026
Johnson & Johnson (Janssen)Pasritamig
FGFR3 inhibitor
FGFR3Phase 3Prostatic Neoplasms, Castration-Resistant; Metastatic Castration-resistant Prostatic Neoplasms; Prostatic Neoplasms; Metastatic Castration-resistant Prostate NeoplasmsJan 2027
National Cancer Institute (NCI)Pazopanib Hydrochloride
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid NeoplasmFeb 2027
Eli LillyVepugratinib (LY3866288)
FGFR3 inhibitor
FGFR3Phase 3Carcinoma, Transitional Cell; Urinary Bladder NeoplasmsJun 2027
AB ScienceMasitinib
Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FGFR3, KIT, PDGFRB, PDGFRAPhase 3Amyotrophic Lateral SclerosisDec 2027
Tyra BiosciencesDabogratinib (TYRA-300)
FGFR3-selective tyrosine kinase inhibitor
FGFR3Phase 2Low-grade NMIBC; Achondroplasia; Low Grade Upper Tract Urothelial Carcinoma; Healthy …Nov 2026
Taiho OncologyFutibatinib (TAS-120)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms …Dec 2026
Tianjin Medical University Cancer Institute and HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Gastrointestinal CancerDec 2026
Shanghai Zhongshan HospitalHRS-4642
FGFR1/2/3/4 inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Biliary Tract Cancer; Pancreatic CancerDec 2026
Sameek RoychowdhuryPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Advanced Pancreatic CarcinomaDec 2026
Tianjin Medical University Cancer Institute and HospitalBemotuzumab
Anti-FGFR3 monoclonal antibody
FGFR3Phase 2Small Cell Lung Cancer (SCLC)Jan 2027
University of UtahPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Relapsed or Refractory B-cell Non-Hodgkin LymphomaMar 2027
UNICANCERPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Solid Tumor, MiscellaneousJun 2027
Mehmet AkcePemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Intrahepatic CholangiocarcinomaJul 2027
National Cancer Institute (NCI)Rogaratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Locally Advanced Gastrointestinal Stromal TumorJul 2027
Ohio State University Comprehensive Cancer CenterPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Locally Advanced Ampulla of Vater CarcinomaDec 2027
Haitao Zhao, MDPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Biliary Tract Cancer (BTC)Dec 2027
Lund University HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Dedifferentiated LiposarcomaDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDonafenib
Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Hepatocellular CarcinomaJan 2028
National Cancer Center, JapanE7090
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Advanced or Recurrent Solid TumorsMar 2028
HutchmedHmpl-453 (HMPL-453)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 2Advanced Intrahepatic CholangiocarcinomaJun 2028
Dana-Farber Cancer InstitutePemigatinib (INCB054828)
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2SDH Gene MutationOct 2028
QED Therapeutics, a BridgeBio companyInfigratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2AchondroplasiaMar 2030
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDerazantinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Intrahepatic Cholangiocarcinoma–
AstraZenecaFexagratinib (AZD4547)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 1Muscle Invasive Bladder Cancer; Metastatic Breast CancerNov 2026
OHSU Knight Cancer InstitutePemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Acute Myeloid LeukemiaDec 2026
Cogent BiosciencesCGT4859
selective FGFR2/3 inhibitor
FGFR2, FGFR3Phase 1Intrahepatic Cholangiocarcinoma (Icc)Mar 2027
Tyra BiosciencesTYRA-200
FGFR 1/2/3 tyrosine kinase inhibitor
FGFR1, FGFR2, FGFR3Phase 1Locally Advanced CholangiocarcinomaMar 2027
EisaiE-7090 (E7090)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 1Hepatic ImpairmentAug 2027
Massachusetts General HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Advanced Solid TumorDec 2027
Tyra BiosciencesTYRA-430
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 1Metastatic Hepatocellular CarcinomaJan 2028
M.D. Anderson Cancer CenterPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Advanced CholangiocarcinomaFeb 2028

Conditions

Non-Muscle Invasive Bladder Neoplasms (3) Colorectal Cancer (3) Hepatocellular Carcinoma (2) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Advanced Cholangiocarcinoma (2) Advanced Solid Tumor (2) Hepatic Impairment (2) Achondroplasia (2) Intrahepatic Cholangiocarcinoma (2) Renal Cell Carcinoma (2) Leiomyosarcoma or Carcinosarcoma (2)

Modalities

small molecule (21), mixed (11), antibody (2), protein or peptide (1)

Companies

Tyra Biosciences (3) Johnson & Johnson (Janssen) (2) National Cancer Institute (NCI) (2) Tianjin Medical University Cancer Institute and Hospital (2) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Taiho Oncology (1) Shanghai Zhongshan Hospital (1) Massachusetts General Hospital (1) Exelixis (1) UNICANCER (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) Eli Lilly (1) TransThera Sciences (Nanjing) (1) Mehmet Akce (1) University of Utah (1) Hutchmed (1) Cogent Biosciences (1) Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)

Related targets

FGFR1 (29) FGFR2 (28) FGFR4 (12) KIT (4) PDGFRA (2) CSF1R (2) LCK (2) MET (1) PDGFRB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.